CASE 3: Unresectable Hepatocellular Carcinoma
Dale P is a 61-year-old Jamaican-American male from Houston, Texas, with a history of HCV infection and cirrhosis, who works in corporate cell-phone sales.
In February of 2012 the patient presented with upper right quadrant discomfort; CT scan showed the presence of a 4.1 × 3.9-cm mass consistent with HCC in the setting of cirrhosis; he was referred to the multidisciplinary team for further assessment.
Initial assessment showed a MELD score of 7 and Child Pugh A class
The patient was not considered appropriate for transplant based on prior history of successfully treated renal cancer (4 years prior) and patient declining to pursue a transplant evaluation
Medical history notable for heavy alcohol use and substance abuse approximately 30 years ago, stroke in mother, deep vein thrombosis in father
Other medical history included nonresponse to pegylated interferon and ribavirin for HCV 5 years earlier; current medications included antihypertensives and aspirin
Patient recommended for liver resection in April 2012
He underwent R0 resection. Pathology showed moderately differentiated HCC with negative margins and no evidence of microvascular invasion
On follow up in April 2013, patient shows no evidence of disease recurrence on MR which is performed every 3 months
On follow up in August of 2014, ~2 years post resection, there is imaging evidence of recurrence and metastasis.
MRI detects multiple lesions at the postsurgical site, largest ~1.7 cm, and a nodule in the inguinal lymph node, ~1.9 x 1.0 cm
Patient’s current assessment shows a MELD score of 9 and Child Pugh A
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More